Home
About Us
Membership
Member Biography

Member Biography

Kathryn Nevel, MD

Kathryn Nevel, MD

Phone: (317) 944-0920
Phone: (317) 944-0920, Patient issues/appointments

355 W. 15th St.
Suite 3200
Indianapolis, IN 46202

Faculty appointments

Assistant Professor of Neurology, Department of Neurology, IU School of Medicine
Associate member, Experimental and Developmental Therapeutics

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation NEUR-AGIOS-AG881-C-004

ART THERAPY IN THE IMPROVEMENT OF PATIENT AND CAREGIVER QUALITY OF LIFE IN THE SETTING OF NEWLY DIAGNOSED HIGH GRADE GLIOMANEUR-IIR-ART-THERAPY

DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent GlioblastomaNEUR-ECOG-ACRIN-EAF151

A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant MorbidityNEUR-SPRINGWORKS-MEK-NF-201

A Randomized, Open-label, Multicentric, Two-arm Pivotal Trial of SonoCloud-9 Combined With Carboplatin (CBDCA) vs Standard of Care Lomustine (CCNU) or Temozolomide (TMZ) in Patients Undergoing Planned Resection for First Recurrence Glioblastoma.NEUR-CARTHERA-SONOBIRD

A Phase 3, Open-label, Randomized 2-arm Study Comparing the Clinical Efficacy and Safety of Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated GlioblastomaNEUR-NEUROTRIALS-NIRAPARIB

Phase Ib Trial of ABBV-637 or ABBV-155 in Combination With ERAS-801 for Glioblastoma With Amplification of the Epidermal Growth Factor ReceptorNEUR-MSKCC-24-409

MOMENTUM-1: A Multicenter, Randomized, Open-Label, Phase II Study of [177LU]LU-DOTATATE in Adults With Progressive Intracranial Grade 1-3 MeningiomaNEUR-RTOG-MOMENTUM-1

#ResearchCuresCancer

Support Our Research